October’s National Family History Month is an important opportunity to emphasize how family history drives cancer risk assessment, genetic referrals, and prevention. Even with growing access to genetic testing, a detailed family history often remains the first and most actionable clue to hereditary cancer risk. Providers and genetic counselors are uniquely positioned to help patients understand why   family health information matters and encourage them to share it with relat

Professor Sir John Burn joined Dr. Swati Patel at the CGA-IGC 2025 Annual Meeting to share long-awaited results from the CaPP3 trial, a follow-up to the landmark CAPP2 study that first demonstrated aspirin’s ability to reduce cancer risk in people with Lynch syndrome.  While some questions remain unanswered and more research is needed, Sir John Burn discusses the results from the study and the considerations surrounding aspirin as a chemopreventive in Lynch syndrome.

The story of CGA-IGC begins in 1995, when James Church suggested that clinicians and researchers in the US who were interested in...